Evita Sadimin, M.D.

(877) 460-4673
Evita Sadimin, M.D.
Pathologist
Clinical Expertise
  • Clinical Informatics
  • Genitourinary Pathology
Academic Appointments
  • Associate Clinical Professor, Department of Pathology
  • Chief, Division of Informatics and Data Science
With the challenge of putting together pieces of information to see the big picture of diagnostic process, research and clinical trials, Dr. Sadimin views her work in urological pathology and pathology informatics as merging her passions for medicine, technology and solving puzzles. Collaborating with physicians and scientists at City of Hope and at other institutions around the world, she contributes to improvement of quality of care, quality of life and outcomes for cancer patients.
 
Dr. Sadimin pursued her medical training at the University of Medicine and Dentistry of New Jersey. At Rutgers Robert Wood Johnson Medical School, she received fellowship training in pathology informatics and residency training in anatomical and clinical pathology, during which she served as chief resident. She subsequently completed a fellowship in urological pathology at Johns Hopkins University.
 
She has great interest in the latest cutting-edge technology and is excited to help lead the digital transformation in pathology, cultivating progress through image analysis and artificial intelligence. As part of the urologic oncology team, her clinical work focuses on cancers of the prostate, bladder, kidney, testis, penis, urethra, and adrenal gland.
 
 

Location

Education & Experience

Board Certifications

  • Clinical Informatics, American Board of Pathology

  • Anatomical and Clinical Pathology, American Board of Pathology

Degrees

  • 2009, M.D. Robert Wood Johnson Medical School, Piscataway, NJ

  • 2003, B.A., Biological Chemistry, Rutgers University, New Brunswick, NJ

Fellowship

  • 2014-2015, Fellow, Genitourinary Pathology, Johns Hopkins Medical Institutions, Baltimore, MD

  • 2011-2012, Fellow, Pathology Informatics, Rutgers Robert Wood John Medical School, New Brunswick, NJ

Residency

  • 2009-2014, Resident in Anatomical and Clinical Pathology, Rutgers Robert Wood John Medical School, New Brunswick, NJ

  • 2012-2013, Chief Resident, Rutgers Robert Wood John Medical School, New Brunswick, NJ

Professional Experience

  • 2021-present, Chief, Division of Informatics and Data Science, Department of Pathology, City of Hope, CA

  • 2021-present, Associate Professor, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, NJ

  • 2020-present, Core faculty, Rutgers Global Health Institute

  • 2018-present, Director of Genitourinary Pathology, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School
    2016-present, Director of Pathology Informatics, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School

  • 2015-2021, Assistant Professor, Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, NJ

Awards & Memberships

Awards

  • 2019, Jerome H. Strauss Award, Binford-Dammin Society of Infectious Disease Pathology

  • 2018, Certificate of Recognition in Data Integration, Rutgers Health

  • 2018, Immuno-Oncology Leadership Cohort Recognition, American Society for Clinical Pathology

  • 2011, Association of Pathology Informatics Travel Award, Association of Pathology Informatics

  • 2003, Bruce Garth Award for Excellence in Chemistry, Rutgers University

  • 2002, Organic Chemistry Excellence Award, Croda International

  • 2002-2003, George H. Cook Honors Scholar, Rutgers University

  • 2000-2003, William H. Martin Scholarship Award, Rutgers University

  • 2000-2003, Class of 1925 Scholarship Award, Rutgers University

Memberships

  • College of American Pathologists, Committee Member

  • United States & Canadian Academy of Pathology

  • Association of Pathology Informatics

  • Genitourinary Pathology Society

  • International Society of Urological Pathology

Publications

  • Foran D, Durbin E, Chen W, Sadimin E, Sharma A, Banerjee I, Kurc T, Li N, Stroup A, Harris G, Gu A, Schymura M, Gupta R, Bremer E, Balsamo J, DiPrima T, Wang F, Abousamra S, Samaras D, Hands I, Ward K, Saltz J. An expandable informatics framework for enhancing central cancer registries with digital pathology specimens, computational imaging tools, and advanced mining capabilities. Journal of Pathology Informatics 2022:13:5.
  • Sterling J, Smith K, Farber N, Nagaya N, Jang T, Singer E, Sadimin E, Kim I. Fourteen-core systematic biopsy that includes two anterior cores in men with PI-RADS lesion equal or greater than 3 is comparable with magnetic resonance imaging-ultrasound fusion biopsy in detecting clinically significant prostate cancer: a single-institution experience. Clinical Genitourinary Cancer 2021:19(4):275-279.
  • Srivastava A, Rivera-Núñez Z, Kim S, Sterling J, Farber N, Radadia K, Patel H, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Sadimin E, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Impact of Pathologic Node Positive Renal Cell Carcinoma on Survival in Patients without Metastasis: Evidence in Support of Expanding the Definition of Stage IV Kidney Cancer. Cancer 2020:126(13):2991-3001.
  • Ren J, Singer E, Sadimin E, Foran D, Qi X. Statistical analysis of survival models using feature quantification on prostate cancer histopathology images. Journal of Pathology Informatics 2019:10:30.
  • Wang L, Zhang Y, Chen Y, Skala S, Al-Ahmadie H, Wang X, Cao X, Veeneman B, Chen J, Cieślik M, Qiao Y, Su F, Vats P, Siddiqui J, Xiao H, Sadimin E, Epstein J, Zhou M, Sangoi A, Trpkov K, Osunkoya A, Giannico G, McKenney J, Argani P, Tickoo S, Reuter V, Chinnaiyan A, Dhanasekaran S, Mehra R. VSTM2A overexpression is a sensitive and specific biomarker for mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney. American Journal of Surgical Pathology 2018:42(12):1571-1584.
  • Sadimin E, Chen Y, Wang L, Argani P, Epstein J. Chromosomal abnormalities of high-grade mucinous tubular and spindle cell carcinoma of the kidney. Histopathology 2017:71(5):719-724.
  • Foran D, Chen W, Chu H, Sadimin E, Loh D, Riedlinger G, Goodell L, Ganesan S, Hirshfield K, Rodriguez L, DiPaola R. Roadmap to a comprehensive clinical data warehouse for precision medicine applications in oncology. Cancer Informatics 2017:16:1-10.
  • Sadimin E, Khani F, Diolombi M, Meliti A, Epstein J. Interobserver reproducibility of percent pattern 4 in prostatic adenocarcinoma on prostate biopsies. American Journal of Surgical Pathology 2016:40:1686-1692.
  • Sadimin E, Epstein J. Round cell pattern of prostatic stromal tumor of uncertain malignant potential: A subtle newly recognized variant. Human Pathology 2016:52:68-73.
  • Sadimin E, Ye H, Epstein J. Should the involvement of skeletal muscle at the prostate apex by prostatic adenocarcinoma be reported on biopsies? Human Pathology 2016:49:10-14.
  • Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: A multi-institutional study. The Journal of Urology 2013:190(2):527-534.
  • Sadimin E, Foran D. Pathology imaging informatics for clinical practice and investigative and translational research. North American Journal of Medicine and Science 2012;5(2):103-109.